Stroke can affect the physical, emotional, and social aspects of patients' lives. The purpose of this study was to assess the feasibility and psychometric properties of a telephone-administered version of the Health Utilities Index Mark 2 and 3 (HUI2/3). Subjects included patients who had had an ischemic stroke within the prior 12 months and their unpaid caregivers (n = 76 pairs) and an additional 33 unpaid caregivers of patients who were generally aphasic or severely affected. Complete response rates, test-retest reliability, and convergent, divergent, and known-groups validity were determined. For patient-caregiver pairs, 27% had no complete Health Utilities Index Mark 2 (HUI2) responses (i.e., had missing responses for at least 1 item of each assessment), 51% had partial responses (i.e., had complete responses for at least 1, but not all of the assessments), and 22% had complete responses. For the Health Utilities Mark 3 (HUI3), the percentages were 19%, 52%, and 29%. Test-retest reliability for patients intraclass correlation coefficient (ICC = 0.76 for HUI2; 0.75 for HUI3) and caregivers (ICC = 0.91 and 0.89, respectively) were excellent. There were generally high levels of both convergent and divergent validity. There was limited known-groups validity (mild v moderately and mild v severely affected patients reported different overall HUI2 and HUI3 scores; there was no difference between those with moderate and severe disabilities). The same pattern was found for caregivers. We conclude that the telephone-administered HUI2/3 appears to be reliable and have at least limited validity. However, the proportions of missing data for patient/caregivers administered the HUI2/3 were surprisingly high. This high proportion of missing data would limit the use of the telephone-administered HUI2/3 in the context of stroke trials.
|Number of pages||8|
|Journal||Journal of Stroke and Cerebrovascular Diseases|
|State||Published - 2002|
Bibliographical noteFunding Information:
This study was supported by a grant from AstraZeneca Pharmaceuticals, Inc. Dr. Albers is a consultant and has participated as an investigator in studies supported by AstraZeneca Pharmaceuticals, Inc. Mr. Rylander is an employee of AstraZeneca Pharmaceuticals, Inc. The study data were obtained and analyzed by the authors. AstraZeneca Pharmaceuticals, Inc., had the opportunity to review and provide comments on the manuscript, but content and final approval remained with the authors.
- Health utilities index
- Quality of life
ASJC Scopus subject areas
- Clinical Neurology
- Cardiology and Cardiovascular Medicine